PROVEXIS PLC Logo

PROVEXIS PLC

PXS | IL

Overview

Corporate Details

ISIN(s):
GB00B0923P27
LEI:
21380042E3Y3N9VZ6N48
Country:
United Kingdom
Address:
2 BLAGRAVE STREET, RG1 1AZ READING
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Provexis PLC is a life sciences company specializing in the development, licensing, and sale of scientifically-proven technologies for the functional food, medical food, and dietary supplement sectors. The company's core asset is Fruitflow®, a proprietary and patented natural ingredient clinically proven to support cardiovascular health. Provexis operates a dual business model, licensing Fruitflow® to international food and supplement companies for use in their products, while also marketing its own branded dietary supplements containing Fruitflow® and Omega-3 directly to consumers and through retail partners.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for PROVEXIS PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-01-07 14:14
Related Party Transaction
Grant of Options and Warrants
English 32.6 KB
2024-12-31 14:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 13.8 KB
2024-12-31 10:59
Interim Report
Half-year Report
English 212.7 KB
2024-12-18 08:00
Major Shareholding Notification
Purchase of Fruitflow® II SD & royalty payment
English 18.8 KB
2024-10-25 16:47
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
English 24.2 KB
2024-09-30 08:00
Earnings Release
Final Results
English 384.9 KB
2024-04-30 18:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 13.7 KB
2024-03-28 08:00
Share Issue/Capital Change
Issue of Equity - purchase of Fruitflow® II SD
English 18.8 KB
2023-12-29 13:48
Earnings Release
Half-year Report
English 198.4 KB
2023-10-26 14:51
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
English 23.8 KB
2023-09-29 08:00
Earnings Release
Final Results
English 374.8 KB
2023-08-30 08:04
Regulatory News Service
BYHEALTH regulatory filing with Chinese SAMR
English 16.5 KB
2023-04-03 08:00
Capital/Financing Update
Capital structure and funding update
English 22.3 KB
2023-01-24 12:03
Remuneration Information
Grant of Share Options
English 34.0 KB
2022-12-30 09:53
Interim Report
Half-year Report
English 203.3 KB

Automate Your Workflow. Get a real-time feed of all PROVEXIS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PROVEXIS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN